Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma Journal Article

  

Authors:	Hakes, T. B.; Chalas, E.; Hoskins, W. J.; Jones, W. B.; Markman, M.; Rubin, S. C.; Chapman, D.; Almadrones, L.; Lewis, J. L. Jr
Article Title:	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
Abstract:	Five versus ten cycles of cyclophosphamide, doxorubicin, and cisplatin (CAP) were compared in advanced ovarian carcinoma by a prospective randomized study of 78 patients, 41 receiving 5 cycles (CAPS) and 37 receiving 10 cycles (CAP10) of chemotherapy. Patients were stratified by histologic grade and size of residual disease. Cyclophosphamide, 600 mg/m2, doxorubicin, 40 mg/m2, and cisplatin, 100 mg/m2, were administered every 4 weeks for 5 or 10 cycles. Second-look laparotomy was performed to evaluate response and plan further therapy. CAPS patients found at second-look laparotomy to have partially responded to chemotherapy were treated with 5 additional cycles of CAP. CAP10 was more toxic than CAPS with respect to myelosuppression, hospital admissions for nadir fever, median elevation of creatinine, and degree of peripheral neuropathy. Median follow-up is 64 months. CAPS and CAP10 were equivalent in surgically documented complete responses (34 versus 35%) and survival (P = 0.41). Twelve partial responders to CAPS received additional CAP chemotherapy; one complete response resulted. We conclude that CAP5 is preferable to CAP10 in treatment of advanced ovarian cancer as it is equally effective and less toxic. © 1992.
Keywords:	adult; cancer survival; survival analysis; major clinical study; cisplatin; doxorubicin; advanced cancer; cancer combination chemotherapy; treatment planning; neoplasm staging; cancer grading; laparotomy; prospective studies; ovarian neoplasms; nephrotoxicity; ovary cancer; bone marrow suppression; tumor volume; antineoplastic combined chemotherapy protocols; peripheral neuropathy; creatinine; cyclophosphamide; creatinine blood level; histology; fever; drug response; carcinoma; second look surgery; intravenous drug administration; human; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title:	Gynecologic Oncology
Volume:	45
Issue:	3
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	1992-06-01
Start Page:	284
End Page:	289
Language:	English
DOI:	10.1016/0090-8258(92)90305-3
PUBMED:	1612505
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026720218&doi=10.1016%2f0090-8258%2892%2990305-3&partnerID=40&md5=b8d093058194887e229b3ccbfc5f4fbb
Notes:	Article -- Export Date: 30 July 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149727